2020
Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation
Steinberg BA, Holmes DN, Pieper K, Allen LA, Chan PS, Ezekowitz MD, Freeman JV, Fonarow GC, Gersh BJ, Hylek EM, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J, Singer DE, Peterson ED, Piccini JP, Mendelson R, Nahhas A, Neutel J, Padanilam B, Pan D, Poock J, Raffetto J, Greengold R, Roan P, Saba F, Sackett M, Schneider R, Seymour Z, Shanes J, Shoemaker J, Simms V, Smiley N, Smith D, Snipes C, Sotolongo R, Staniloae C, Stoltz S, Suresh D, Tak T, Tannenbaum A, Turk S, Vora K, Randhawa P, Zebrack J, Silva E, Riley E, Weinstein D, Vasiliauskas T, Goldbarg S, Hayward D, Yarlagadda C, Laurion D, Osunkoya A, Burns R, Castor T, Spiller D, Luttman C, Anton S, McGarvey J, Guthrie R, Deriso G, Flood R, Fleischer L, Fierstein J, Aggarwal R, Jacobs G, Adjei N, Akyea-Djamson A, Alfieri A, Bacon J, Bedwell N, Berger P, Berry J, Bhagwat R, Bloom S, Boccalandro F, Capo J, Kapadia S, Casanova R, Morriss III J, Christensen T, Elsen J, Farsad R, Fox D, Frandsen B, Gelernt M, Gill S, Grubb S, Hall C, Harris H, Hotchkiss D, Ip J, Jaffrani N, Jones A, Kazmierski J, Waxman F, Kneller G, Labroo A, Jaffe B, Lebenthal M, Lee D, Lillestol M, LeClerc K, Maccaro P, Mayer N, Kozlowski J, Benjamin S, Detweiler R, Igic P, Jackson T, Pappas J, Littlefield R, Frey A, Vranian R, Long W, Grena P, Arouni A, Quinn J, Browne K, Forman S, Ebinger M, Blonder R, Snyder H, Slabic S, Williams D, Stein R, Kirkland S, Cohen K, Walthall W, Davis K, Snoddy B, Alvarado O, Leach C, Rothman S, Sharma A, Olatidoye A, AlMahameed S, Rosenthal S, Sutter G, Reiter W, Thompson T, Thew S, Kobayashi J, Williams M, Kramer J, Latif S, Rhee B, Adler A, Ruiz-Serrano D, Stringam S, Wolok K, Focil A, Butman S, Ingersoll H, Borge R, Al-Saghir Y, Coats P, Farris N, Shore K, Schwartz M, Gornick C, Eilat P, Quinlan E, Paliwal Y, Mitra R, Jingo A, Aslam A, Watson R, Voyce S, Turakhia M, Goytia-Leos D, Lurie M, Mallis G, Atwater B, Strobel J, Murray J, Fisher D, Atieh M, Landes R, Drabick A, Harman E, Ashcraft B, Krista M, Videlefsky A, Rivera Zayas E, Tan A. Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation. Circulation Arrhythmia And Electrophysiology 2020, 13: e007775. PMID: 32298144, PMCID: PMC7247417, DOI: 10.1161/circep.119.007775.Peer-Reviewed Original ResearchConceptsAntiarrhythmic drug useHRQoL improvementAtrial fibrillationPrior stroke/transient ischemic attackStroke/transient ischemic attackDrug useBaseline diastolic blood pressureChronic obstructive pulmonary diseaseAtrial Fibrillation EffectAF risk factorsTransient ischemic attackPeripheral arterial diseaseBetter Informed TreatmentDiastolic blood pressureHealth-related qualityObstructive pulmonary diseasePatient-reported outcomesQuality of lifeIschemic attackHigh-value careBlood pressurePulmonary diseaseArterial diseaseMultivariable analysisOutcomes Registry
2019
Comparison of Long-Term Adverse Outcomes in Patients With Atrial Fibrillation Having Ablation Versus Antiarrhythmic Medications
Freeman JV, Tabada GH, Reynolds K, Sung SH, Singer DE, Wang PJ, Liu TI, Gupta N, Hlatky MA, Go AS. Comparison of Long-Term Adverse Outcomes in Patients With Atrial Fibrillation Having Ablation Versus Antiarrhythmic Medications. The American Journal Of Cardiology 2019, 125: 553-561. PMID: 31843233, PMCID: PMC6987016, DOI: 10.1016/j.amjcard.2019.11.004.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Arrhythmia AgentsAtrial FibrillationCaliforniaCatheter AblationFemaleHumansMaleMiddle AgedPropensity ScoreConceptsTransient ischemic attackChronic antiarrhythmic therapyHeart failure hospitalizationIschemic attackAntiarrhythmic therapyAF ablationIschemic strokeIntracranial hemorrhageAntiarrhythmic medicationsFailure hospitalizationCatheter ablationAdverse outcomesAdjusted ratesKaiser Permanente Northern CaliforniaLong-term adverse outcomesAtrial fibrillation catheter ablationAF catheter ablationHigh-dimensional propensity scoreHistory of diabetesHistory of hypertensionCoronary heart diseaseHealthcare delivery systemCause hospitalizationObservational cohortHeart failurePatterns of amiodarone use and outcomes in clinical practice for atrial fibrillation
Pokorney SD, Holmes DN, Shrader P, Thomas L, Fonarow GC, Mahaffey KW, Gersh BJ, Kowey PR, Naccarelli GV, Freeman JV, Singer DE, Washam JB, Peterson ED, Piccini JP, Reiffel JA. Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. American Heart Journal 2019, 220: 145-154. PMID: 31812756, DOI: 10.1016/j.ahj.2019.09.017.Peer-Reviewed Original ResearchConceptsUse of amiodaroneAmiodarone useAntiarrhythmic drugsAtrial fibrillationAF patientsDifferent antiarrhythmic drugsGuideline-based indicationsPropensity-matched cohortEffective antiarrhythmic drugProportional hazard modelingORBIT-AF registryLogistic regression modelsHierarchical logistic regressionCause mortalityAF RegistryCardiovascular hospitalizationAmiodaroneHigh incidencePatientsClinical practiceHazard modelingLogistic regressionAdverse effectsRandom interceptFibrillation
2018
Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF
Washam JB, Holmes DN, Thomas LE, Pokorney SD, Hylek EM, Fonarow GC, Mahaffey KW, Gersh BJ, Kowey PR, Ansell JE, Go AS, Reiffel JA, Freeman JV, Singer DE, Naccarelli G, Blanco R, Peterson ED, Piccini JP. Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF. Journal Of The American Heart Association 2018, 7: e008928. PMID: 30371218, PMCID: PMC6222961, DOI: 10.1161/jaha.118.008928.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAged, 80 and overAnti-Arrhythmia AgentsAnticoagulantsAtrial FibrillationDabigatranDrug Therapy, CombinationFemaleFollow-Up StudiesHumansMaleMiddle AgedProspective StudiesRegistriesRenal Insufficiency, ChronicRisk FactorsStrokeTime FactorsTreatment OutcomeWarfarinConceptsBackground Chronic kidney diseaseAntiarrhythmic drug useTransient ischemic attackChronic kidney diseaseAtrial fibrillationAdvanced CKDCKD statusIschemic attackSystemic embolismCause mortalityCreatinine clearanceRhythm controlKidney diseaseDrug useAtrial fibrillation scoreBaseline renal functionOral anticoagulant useRhythm control strategyCox proportional hazardsCKD patientsMajor bleedingOAC useCardiovascular deathCKD stageHigher CHACharacteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation
Durheim MT, Holmes DN, Blanco RG, Allen LA, Chan PS, Freeman JV, Fonarow GC, Go AS, Hylek EM, Mahaffey KW, Pokorney SD, Reiffel JA, Singer DE, Peterson ED, Piccini JP. Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. Heart 2018, 104: 1850. PMID: 29875139, DOI: 10.1136/heartjnl-2017-312735.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnti-Arrhythmia AgentsAnticoagulantsAtrial FibrillationComorbidityFemaleHealth StatusHeart Conduction SystemHemorrhageHospitalizationHumansLungMalePrevalencePulmonary Disease, Chronic ObstructiveQuality of LifeRegistriesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseAtrial fibrillationSymptom burdenHeart failurePulmonary diseaseHigh riskDiagnosis of COPDNew-onset heart failureTreatment of AFBeta-blocker useCardiovascular risk factorsMajor bleeding eventsHigh symptom burdenBetter Informed TreatmentCoronary artery diseaseOutcomes of adultsQuality of lifeBleeding eventsDigoxin useBlocker useCause mortalityProspective registryReversible causesCardiovascular mortality
2014
Digoxin and Risk of Death in Adults With Atrial Fibrillation
Freeman JV, Reynolds K, Fang M, Udaltsova N, Steimle A, Pomernacki NK, Borowsky LH, Harrison TN, Singer DE, Go AS. Digoxin and Risk of Death in Adults With Atrial Fibrillation. Circulation Arrhythmia And Electrophysiology 2014, 8: 49-58. PMID: 25414270, PMCID: PMC4334705, DOI: 10.1161/circep.114.002292.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAnti-Arrhythmia AgentsAtrial FibrillationCaliforniaChi-Square DistributionDigoxinFemaleHospitalizationHumansKaplan-Meier EstimateMaleMiddle AgedPatient SelectionPropensity ScoreProportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsTreatment OutcomeConceptsRisk of deathIncident atrial fibrillationAtrial fibrillationDigoxin useHigh riskHeart failureIndependent associationPropensity score-matched adultsKaiser Permanente NorthernPrevious heart failureRetrospective cohort studyResearch Network StudySubgroups of ageCohort studyCox regressionAdverse outcomesRisk factorsHospitalizationFibrillationDigoxinDeathLimited dataAdultsRiskHigh rate